

International Stem Cell Corp. (ISCO.OB): - a biotechnology company focusing on therapeutic and research products. ISCC's proprietary technology, Parthenogenesis, produces pluripotent (capable of becoming any cell in the body) human stem cell lines from unfertilized human eggs. ISCC have also created the first Parthenogenetic homozygous stem cell line, which can be a source of therapeutic cells that will not be immune rejected after transplantation into individuals of differing sexes, ages and racial groups. These advancements offer the potential to create the first true "Stem Cell Bank" and address ethical issues by eliminating the need to use or destroy fertilized embryos. ISCO also produces and markets specialized cells and growth media worldwide for therapeutic research through its subsidiary Lifeline Cell Technology.